Bristol-Myers to buy Celgene in a $74 billion deal

127
KEY POINTS
  • Bristol-Myers Squibb announce plans to buy Celgene in a cash and stock deal valued at $74 billion.
  • Celgene shareholders will receive one Bristol-Myers Squibb share and $50 in cash for each share held, or $102.43 per share.
  • Shares of Celgene surge in premarket trading, while Bristol-Myers Squibb shares fall.

Source https://www.cnbc.com/2019/01/03/bristol-myers-to-buy-celgene-in-a-74-billion-deal.html